Pablo J Cagnoni
CIK 1205703 · President, Global Head of R&D · last filed 2026-10-19
Pablo J Cagnoni is a President, Global Head of R&D who has filed 61 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for INCY, was dated Oct 19, 2026. Across all open-market trades the lifetime net is −$17.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $21.8M across reported positions. 28 SEC filings were submitted jointly with INCYTE CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
249 E. GRAND AVE.
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | President, Global Head of R&D | 185,842 | $115.53 | $21.47M | -$15.71M | 23 | 2026-10-19 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | CEO and President | 66,082 | $0.08 | $5.5K | $50.6K | 8 | 2023-02-01 |
| CRSP | Director | 7,500 | $49.20 | $369.0K | -$1.73M | 6 | 2019-11-21 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | — | — | — | $0 | 2 | 2017-06-02 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP, Global R&D and Tech Ops | 16,257 | — | — | $0 | 1 | 2013-03-13 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Sr. VP, Chief Medical Officer | 25,200 | — | — | -$73.3K | 6 | 2009-10-02 |
Recent Filings
61 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-19 | INCY | Mixed | — | -$124.0K | EDGAR |
| 2026-10-15 | INCY | Notice (144) | −2,642 | -$297.8K | EDGAR |
| 2026-09-17 | INCY | Mixed | — | -$1.26M | EDGAR |
| 2026-09-15 | INCY | Notice (144) | −23,218 | -$2.80M | EDGAR |
| 2026-08-20 | INCY | Sell (S) | −10,801 | -$1.36M | EDGAR |
| 2026-08-19 | INCY | Notice (144) | −10,801 | -$1.36M | EDGAR |
| 2026-08-14 | INCY | Sell (S) | −10,803 | -$1.30M | EDGAR |
| 2026-08-12 | INCY | Notice (144) | −10,803 | -$1.30M | EDGAR |
| 2026-08-07 | INCY | Sell (S) | −10,640 | -$1.31M | EDGAR |
| 2026-08-07 | INCY | Sell (S) | −10,640 | -$1.31M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.